Company intelligence / Profile preview

The Savoy

Salt Lake City, Utah, United States

Ownership: Private
Development stage: Other

Overview

Savoy Pharmaceuticals is a biotechnology company focused on developing targeted immunotherapies for cancer and viral diseases. The company's lead candidate, Oncoprev, is a humanized monoclonal antibody that targets Thymidine Kinase 1 (TK1), a protein expressed on the surface of cancer cells and virus-infected cells but not on normal cells. Savoy's technology aims to provide safer and more effective treatments for a variety of indications, including hepatocellular carcinoma, hepatitis C, and HIV. The company is currently advancing its lead programs through IND-enabling studies to enter clinical trials.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Monoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on The Savoy.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on The Savoy.

Explore the full profile